Survodutide vs Retatrutide: What the Phase 3 Trials Show

By The RX Index Editorial Team · Last verified October 15, 2026

Survodutide vs retatrutide: retatrutide reported higher average weight loss in separate Phase 3 trials — 28.3% vs 16.6% without diabetes, and 20.8% vs 13.1% with type 2 diabetes. These estimates assume treatment as planned. Survodutide has biopsy-based liver evidence. Neither is FDA-approved, and these trials did not compare them directly.

Those are the "if taken as planned" numbers. Include people who stopped treatment, and all four drug averages fall — but retatrutide's reported averages are still higher. The table below shows both versions side by side.

RX Index Decision Verdict: Retatrutide has the higher reported weight-loss averages. Survodutide has biopsy evidence for MASH — fatty liver disease with inflammation and cell injury. Neither is approved for routine prescribing. For care now, the access section separates approved options, clinical trials, and limited expanded access.

• Best for: Understanding where these two drugs really stand before you talk to a doctor, look at a trial, or decide whether to wait.
• Not ideal for: Choosing a vial to buy or finding a dose. Neither has an FDA-approved retail product or approved dose.
• The factor that matters most: Finding the relevant trial population. If you have type 2 diabetes, start with the diabetes rows. They are group averages, not your expected result.

Survodutide vs retatrutide: which loses more weight?

Retatrutide reported higher average weight loss in both pairs of Phase 3 trials shown here — one pair without diabetes, one pair with type 2 diabetes. These were separate trials, each against its own placebo group. They don't prove which drug would work better for any one person.

Here's the rule we used: group the trials by diabetes status and compare the same kind of reported estimate. That makes the differences easier to read; it does not make the participants, trial rules, or study lengths identical. Each row shows the highest assigned dose in that trial. "Randomized" means assigned to a study group by chance. The dose numbers name research groups. They are not approved doses, equivalent doses, or instructions for taking either drug.

The four-trial table

Average body-weight loss at the end of each trial. Every drug result is compared with that same trial's placebo group. Separate trials, not a head-to-head. The survodutide analyses included randomized participants who received at least one dose. Sources: Lilly's TRIUMPH-1 release and NEJM abstract; the SYNCHRONIZE-1 paper; Lilly's TRIUMPH-2 release and Lancet abstract; and the SYNCHRONIZE-2 paper and supplement. Checked October 15, 2026.

Now subtract each trial's own placebo average from its drug average. This shows the difference within each study; subtracting those differences does not create a head-to-head trial:

The RX Index arithmetic from the rounded averages in the table above. A "point" is one percentage point of body weight. These subtractions can differ by 0.1 point from a paper's reported treatment difference because of rounding and statistical estimation. The last column is descriptive math across separate trials, not a tested drug-versus-drug effect.

The displayed difference is smaller in the diabetes trials. That is a pattern in these four studies, not proof that diabetes changes the difference between the drugs.

Why does each trial report two numbers?

Each number answers a different question. The "if taken as planned" number (researchers call it the efficacy estimand) estimates what would happen if participants followed the assigned treatment plan. It is not simply an average of people who finished. The "including treatment stops" number (the treatment-regimen estimand) includes the effects of stopping treatment or starting other treatments under the study's rules. Both use statistical methods to deal with missing measurements.

Think of it like grading a cooking class. One estimate asks how the class would do if everyone followed the course. The other asks how the class did with dropouts included. Neither means you know every missing student's final grade.

Including treatment stops helps show why staying on treatment matters. Survodutide's average falls more between these two analyses, and more participants stopped it in the trials shown here. But these are still controlled studies, not a prediction of your result in everyday care. See the side-effects section for the stopping rates and trial rules.

How placebo-adjusted weight loss works →

One catch that makes survodutide look worse than it may be

Survodutide's placebo group lost 5.4% on the "including treatment stops" estimate. The SYNCHRONIZE-1 paper reports that 16.5% of the placebo group used a GLP-1 medicine the study did not allow, usually after stopping assigned placebo while remaining in follow-up.

When the placebo group loses more, the drug's difference from it looks smaller. Outside GLP-1 use could narrow that difference, but this comparison cannot tell you by how much. Even so, the reported drug averages remain 13.0% for survodutide and 25.0% for retatrutide, and the "if taken as planned" estimates show the same ordering.

What does the gap mean in pounds?

This turns the calculated drug-minus-placebo percentages into pounds at a few hypothetical starting weights. It's arithmetic on group averages from separate trials — not a forecast for you or a report of what people at each weight actually lost.

Uses the "if taken as planned" differences calculated above: 26.1 vs 13.4 points (no diabetes) and 16.8 vs 10.0 points (type 2 diabetes). Formula: hypothetical starting weight × points ÷ 100. Values are rounded to the nearest pound, with half-pounds rounded up. A starting weight alone does not establish treatment eligibility.

Say the hypothetical starting weight is 250 pounds, using the no-diabetes rows. The calculations are 250 × 26.1% = 65.25 pounds and 250 × 13.4% = 33.5 pounds. Their difference is 31.75 pounds, or about 32 pounds. These are scaled percentages from separate trials, not observed results for a 250-pound person.

Not sure whether you have type 2 diabetes? Prediabetes is not the same thing. Your diagnosis and treatment history matter, not just your latest A1C result (a blood test of your average blood sugar). Someone with well-controlled diabetes does not belong in a no-diabetes trial just because their current A1C is low. If you don't know, read both and ask your doctor which population is relevant.

Why you've seen different numbers elsewhere

Many pages still compare older, smaller trials. Retatrutide's well-known 24.2% came from a 48-week Phase 2 trial. Survodutide's nearly 19% headline came from its 46-week Phase 2 actual-treatment analysis, not the same analysis used for its main 14.9% result. You may also have seen 30.3% for retatrutide. That came from a selected 104-week extension in 532 participants with a starting body mass index (BMI, a measure based on height and weight) of at least 35 who completed 80 weeks and tolerated their assigned dose — not everyone who started.

The Phase 3 numbers above come from bigger, longer trials. They are more useful for this comparison than mixing a Phase 2 headline with a selected extension.

If you're curious whether "three targets beats two" holds up across more drugs, see our research comparison in triple agonist vs dual agonist weight loss. For more retatrutide trial results, see retatrutide weight loss results.

Before you choose anything

Comparing two future drugs is different from choosing care you can start now. For that, the right GLP-1 path depends on your state, your insurance and formulary (your plan's list of covered drugs), whether you want an FDA-approved or a compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows suggested GLP-1 paths and providers to review. It's free, takes about 2 minutes, and needs no signup. It can't get you survodutide or retatrutide or decide whether a medicine is safe for you, and it doesn't check your actual coverage or copay.

See which GLP-1 paths fit you

How are survodutide and retatrutide different?

Survodutide turns on two hormone signals: GLP-1 and glucagon. Retatrutide turns on three: GLP-1, GIP, and glucagon. Both are once-weekly shots under the skin, both are still being tested, and neither has an FDA-approved version. (Trial evidence; survodutide program).

Three plain-word definitions first:

• GLP-1 (glucagon-like peptide-1) is one of the body's "I'm full" signals. It tells your brain you've eaten enough and slows how fast your stomach empties.
• GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works alongside GLP-1.
• Glucagon is a hormone that acts mainly on the liver and on how your body uses energy.

A drug that switches on one of these signals is called an agonist. Think of each signal as a doorbell. Survodutide rings two. Retatrutide rings three.

Sources: Boehringer Ingelheim, Oct 1, 2026; Eli Lilly, July 23, 2026. Checked October 15, 2026.

One more bell doesn't automatically mean a better drug. Doses differ, the molecules differ, and the trials differ. What the table can't tell you is how much of the difference between the reported averages comes from the extra signal itself.

Which has worse side effects?

Both drugs commonly caused stomach and bowel side effects, mostly while the dose was going up. In the trials without diabetes, about 1 in 4 people on the top survodutide dose stopped assigned treatment because of an adverse event, versus about 1 in 9 on the top retatrutide dose. Both studies also recorded dysesthesia — odd skin sensations. These separate trials cannot establish which drug is safer.

An "adverse event" is any health problem recorded during the study. It isn't always proven to come from the drug, which is why each one is compared with placebo. The tables show selected events, not every risk. Stopping the assigned drug is not the same thing as leaving the study.

Without diabetes (highest dose of each)

Sources: SYNCHRONIZE-1, Table 3; Lilly's TRIUMPH-1 release. Each placebo percentage belongs to its own trial. Separate trials with different rules — not a head-to-head safety ranking. "Not given" describes the retrieved report, not a zero event rate. Checked October 15, 2026.

With type 2 diabetes (highest dose of each)

Sources: SYNCHRONIZE-2, Table 3; Lilly's Sept 29 TRIUMPH-2 report; the original Lancet abstract. Checked October 15, 2026.

Lilly labels 7.7% vs 4.9% as stopping due to adverse events; the Lancet abstract reports 22/286 vs 14/287 as stopping due to adverse events or death. SYNCHRONIZE-2 reported no deaths. †The blood-pressure groupings also differ: survodutide's includes syncope (fainting); retatrutide's covers low blood pressure, a fall on standing, or decreased blood pressure. Do not treat these as identical safety endpoints.

The stomach-only stopping figure does not tell the whole story. In SYNCHRONIZE-2, 17.9% at 6.0 mg stopped because of stomach or bowel events, while 25.9% stopped because of any adverse event. Those are different measures. Neither is the percentage who stopped for every possible reason, and neither proves a head-to-head tolerability advantage.

Boehringer's side of the story, stated fairly: its trials initially allowed little flexibility in how fast the dose went up; some rules were relaxed late, and its newer trials test a gentler, more flexible approach. That may lower the quit rate. It hasn't been shown yet. (Trial methods; Boehringer's Oct 1 update).

Why this matters to you: a drug you can't stay on may not be a workable long-term treatment. The biggest average in the world means little if you're one of the people who stops in month two.

For the full list by dose, see retatrutide side effects. For how trial quit rates are counted, see GLP-1 trial dropout rates explained.

Does either raise your heart rate?

Both have. In SYNCHRONIZE-1, average resting heart rate on survodutide rose by 3.2 to 3.5 beats per minute from baseline at week 76; placebo fell by 0.4. In retatrutide's Phase 2 trial, heart rate rose with higher doses, peaked around week 24, and then came back down. Neither trial shows that one is safer for your heart.

If you already have a fast pulse or a heart condition, that's a question for your own doctor or a trial team, not a receptor chart.

Does either protect muscle better?

The studies reviewed do not establish a muscle-preservation winner. In a 75-person MRI substudy of SYNCHRONIZE-1, Boehringer's corrected estimate put lean tissue at 11.3% of the change in total tissue mass at the highest dose. An additional analysis put muscle at no more than 10% of tissue lost. These are estimates from a selected subgroup, not a limit on how much muscle any one person could lose. (Corrected lean-tissue report; muscle analysis). We didn't find a direct comparison with retatrutide that settles this question. And a body scan isn't a strength test.

Lean mass loss by GLP-1 drug →

Is survodutide better for fatty liver?

Survodutide has biopsy-based MASH evidence and a large Phase 3 liver program. Retatrutide also cut liver fat sharply in an earlier MRI study. The two studies measured different things, so they can't crown a liver winner.

First, the terms:

• MASLD (metabolic dysfunction-associated steatotic liver disease) means extra fat in the liver, tied to things like weight and blood sugar. It used to be called fatty liver disease or NAFLD.
• MASH (metabolic dysfunction-associated steatohepatitis) is the more serious form: fat plus inflammation and liver-cell damage.
• Fibrosis means scarring. More scarring is more serious.
• MRI-PDFF is an MRI scan that measures what share of the liver is fat.

Sources: the survodutide biopsy trial, the corrected SYNCHRONIZE-MASLD paper, and the retatrutide MRI substudy. These are different liver endpoints, not a direct comparison. MASH improvement is not the same as MASH resolution, and neither is the same as less liver fat. Checked October 15, 2026.

Why "84%" and "82%" don't mean the same thing

They look close. They aren't the same kind of number.

Survodutide's 84.2% is a share of people who hit a goal (a 30% drop). Retatrutide's 82.4% is the average size of the drop. Neither number tells you whether scarring got better.

A quick example with made-up numbers: if your liver fat goes from 20% to 10%, that's a 50% drop — but only 10 percentage points. And it says nothing about inflammation or scarring, which only a biopsy or other tests can judge.

That's why survodutide's biopsy study matters. It's the only one here that directly checked MASH improvement on a biopsy, not just liver fat or blood markers. According to Boehringer Ingelheim, the FDA gave survodutide Fast Track (May 2021) and Breakthrough Therapy (September 2024) designations for noncirrhotic MASH with moderate or advanced fibrosis, not for weight loss. Neither is an approval. Its Phase 3 liver program includes LIVERAGE (planned enrollment about 1,800 adults) and LIVERAGE-Cirrhosis (about 1,590). A program's planned size does not show whether a site is enrolling now.

If a liver diagnosis is why you're here

You don't have to wait for either drug to discuss liver treatment. Wegovy injection, not the Wegovy pill, received FDA accelerated approval in August 2025 for adults with MASH and moderate-to-advanced scarring (F2–F3) without cirrhosis. Continued approval depends on confirming clinical benefit. It's not the only approved MASH treatment: the FDA approved Rezdiffra in 2024. Take your diagnosis, your fibrosis stage, and these study details to your doctor or a liver specialist. (Wegovy labeling; FDA MASH announcement; Rezdiffra approval).

Best GLP-1 for fatty liver →

With type 2 diabetes, which helps blood sugar more?

Both lowered A1C in their diabetes trials. Retatrutide lowered it by about 1.5 points from a starting average of 7.7%. Survodutide lowered it by up to 1.21 points from 7.4%. The trials started in different places, so this isn't a clean contest.

Sources: Boehringer Ingelheim, Oct 1, 2026; Eli Lilly, Sept 29, 2026. Lilly notes its normal-A1C result wasn't adjusted for multiple comparisons. Boehringer describes its normal-A1C maximum during treatment, so that row is not a same-time-point comparison. A low A1C while taking treatment does not show that diabetes is cured. Checked October 15, 2026.

Two things to know. First, SYNCHRONIZE-2 did not include people taking insulin. If you use insulin, these results may not describe you. Second, the 28.3% headline came from people without diabetes. The 20.8% and 13.1% estimates came from type 2 diabetes populations — still not a forecast of what you would lose.

When could you get survodutide or retatrutide?

Neither drug is FDA-approved, and neither has a confirmed approval date. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. Boehringer's October 1 update gives no U.S. submission date for survodutide.

Sources: Lilly's July 23 report and Sept 29 report; Boehringer's Oct 1 update; Lilly's official TRIUMPH-5 listing; SYNCHRONIZE-CVOT, NCT06077864. Trial dates and company plans can change. TRIUMPH-5 compares retatrutide with tirzepatide, not survodutide.

A filing is the start of a review, not the end. Here's the usual path:

1. The company submits its application.
2. For a new drug or original biologics application, the FDA generally uses an initial 60-day filing review to decide whether the package is complete enough to review.
3. Under the FDA's usual review goals, the agency aims to act on 90% of priority applications within 6 months, or standard applications within 10 months, after the filing date. These are goals, not guaranteed approval times.
4. The FDA approves the drug or sends back a letter explaining what must be addressed before approval.

Those are the usual FDA review goals, not a confirmed schedule for either drug. Other programs can shorten review, and a review can also be extended. Anyone handing you a firm approval date for either drug is guessing. We won't.

How the FDA approves obesity drugs →

Can you buy survodutide or retatrutide now?

Not as an FDA-approved retail prescription. The FDA has named both in its warning about unapproved products sold for human use despite "research" labels, and it says retatrutide cannot be used in compounding under federal law. Legitimate clinical trials and limited expanded access are different from buying a vial online.

That's straight from the FDA's page on unapproved GLP-1 drugs (updated October 1, 2026). The same page reminds readers that compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they're sold. Its explicit compounding statement names retatrutide, not survodutide; that difference is not permission to buy a product sold as survodutide.

A seller's vial label cannot prove what's inside it, how much, or whether it's sterile. A "research use only" label doesn't make it safe for a person. The FDA warns that these illegally marketed products are of unknown quality and can be harmful.

If you've taken something sold as either drug and feel unwell, call Poison Control at 1-800-222-1222. If someone collapses, can't breathe, or won't wake up, call 911.

How to avoid fake GLP-1 medicines online →

What would they cost?

Commercial prices, insurance coverage, and savings programs for an FDA-approved product are not established for either drug. Prices you see on research-peptide sites are not the price of an approved prescription. Treat any "expected price" as a guess. There is one separate cost fact: Lilly says it supplies retatrutide at no charge through its limited expanded-access program. That does not establish that visits, tests, or travel are free.

How do you find a real clinical trial?

Clinical trials are one legitimate way to receive an investigational drug before approval. Participation does not guarantee you will receive the drug rather than placebo or another study treatment. Search ClinicalTrials.gov for "survodutide" or "retatrutide," filter by your location and "recruiting," then call the listed site. A study being listed doesn't mean it's enrolling, nearby, or right for you.

Questions worth asking the study team:

• Is this site enrolling right now?
• Could I get placebo instead of the drug?
• How many visits, and what's covered?
• What happens when the study ends?
• Who do I call if I have side effects?

For retatrutide, Lilly also supports limited expanded access that a treating doctor has to request. It is for exceptional cases: adults whose obesity has not responded enough to standard treatment (BMI at least 35), at least two serious obesity-related complications, and no suitable trial access, after standard options have been discussed. Lilly reviews each case, and access also depends on geography, supply, and regulatory requirements. It isn't a public signup or a way to buy the drug. Start with your treating doctor, not a seller. Retatrutide availability and research access →

Should you wait for one, or start something now?

You don't have to wait for a future drug to talk about treatment today. FDA-approved options can be prescribed now, with a label, a tested dose plan, and a doctor who can adjust it. Waiting for a future drug is a choice to discuss with your doctor, not something these headlines require.

Here's the honest part. Zepbound (tirzepatide) does not match retatrutide's 28.3% headline in the trials discussed here. Its label's 72-week study without diabetes reported up to 20.9%, using a different analysis from that retatrutide headline. These are not head-to-head results, and we won't pretend the figures are interchangeable. But Zepbound is already FDA-approved: a doctor can discuss a real treatment option now, rather than a possible future one. Whether you get a prescription and when you can start still depend on clinical fit, cost, coverage, and supply.

Find yourself in this table:

If you decide to start an FDA-approved medicine, telehealth services can help. Ro's current program lists Zepbound and Wegovy injections with insurance or cash-pay options and help with prior authorization — the paperwork asking a plan to cover a drug. It lists Foundayo as cash-pay only; insurance support for other drugs does not make Foundayo covered through Ro. Read our Ro review before you choose. For a wider look, see alternatives to waiting for survodutide and current alternatives to retatrutide.

For adults exploring weight-loss care now, two quick questions can tell you a lot. Is your BMI 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? And do you know whether your plan covers weight-loss medicine? Those weight thresholds appear in common prescribing criteria, but they are not a full eligibility check. The tool helps sort paths; a clinician decides whether a medicine fits, and your plan confirms coverage. You can still read the options when you don't know your BMI or coverage.

Get your GLP-1 path in about 2 minutes

Should you stop a GLP-1 you're on now to wait? No — not because of this page or any headline. That decision belongs to you and the doctor managing your prescription.

How we checked this comparison

We grouped trials by diabetes status and the kind of number they reported, showed each trial's placebo group, and checked the figures against the primary material identified below. We recalculated the arithmetic separately. We didn't test either drug, and we didn't re-analyze patient-level trial data.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified (October 15, 2026)

• Weight and safety results: the full SYNCHRONIZE-1 paper and the SYNCHRONIZE-2 paper and supplement, including their safety tables; the original TRIUMPH-1 and TRIUMPH-2 abstracts; and Lilly's May 21 and September 29 reports. We did not have the complete TRIUMPH papers for this check.
• Liver and muscle results: the survodutide MASH biopsy paper, the corrected SYNCHRONIZE-MASLD article, the retatrutide MRI substudy, and Boehringer's corrected lean-tissue release and October 1 muscle report. The 11.3% lean-tissue estimate is the company's corrected figure, not the 10.8% in the older PDF copy.
• Approval and access: the FDA's unapproved-GLP-1 page; current Wegovy labeling; FDA's Foundayo and Rezdiffra announcements; and Lilly's physician-facing expanded-access page, last reviewed by Lilly on August 26, 2026.
• Filing plans: Lilly's Q1 2027 plan, repeated September 29; no U.S. submission date in Boehringer's October 1 update; and Lilly's official TRIUMPH-5 listing. A company plan is not an FDA deadline.
• What's company-reported: the trial programs were company-funded. Some detailed figures here come from the drugmakers' releases and are identified that way; they are not independently replicated by The RX Index.
• What we couldn't confirm: an approval date for either drug, future commercial prices or personal insurance coverage, enrollment at a particular trial site, individual expanded-access eligibility or related medical costs, and the retatrutide stomach-event totals not supplied in the primary reports retrieved. We checked Ro's listed offerings and the quiz description, not an intake, insurance decision, or checkout.

Our provider ratings are not ratings of these investigational drugs. See our methodology →

Frequently asked questions

Is retatrutide better than survodutide?

For weight loss, retatrutide's reported averages are higher in both sets of Phase 3 trials — with and without type 2 diabetes. But those were separate trials, not a direct test in the same people. Survodutide has biopsy-based MASH evidence; lower reported stopping rates for retatrutide do not settle which is safer. Neither is FDA-approved.

Which one raises heart rate less?

The trials don't settle that. Survodutide raised average heart rate by about 3 beats per minute at 76 weeks, and retatrutide's Phase 2 trial showed a dose-related rise that peaked and then eased. If you have a heart condition or a fast pulse, talk it over with your doctor or a trial team. (Survodutide trial; retatrutide Phase 2 trial).

Does survodutide save more muscle than retatrutide?

That hasn't been shown. Boehringer's corrected MRI-substudy estimate puts lean tissue at 11.3% of total tissue change at the highest dose, not a maximum for every patient. We found no direct comparison that establishes better muscle protection than retatrutide, and a scan isn't a strength test.

Will insurance cover survodutide or retatrutide?

Nobody can confirm future commercial coverage yet. Neither drug is FDA-approved, so an approved label, commercial terms, and your plan's decision are still separate unknowns. Retatrutide's limited expanded-access program is a different pathway, not ordinary pharmacy coverage.

When will survodutide and retatrutide be approved?

There's no approval date for either. Lilly plans to file retatrutide with the FDA in the first quarter of 2027. Boehringer's October 1 update gives no U.S. filing date for survodutide. A filing starts a review that usually takes many months. (Lilly; Boehringer).

Can you take survodutide and retatrutide together?

The four trials compared above tested one drug against placebo, not the two drugs together. They do not establish a safe or effective combination. Online "stacking" advice does not fill that evidence gap and is not a substitute for medical care.

Is retatrutide a "GLP-3"?

No. "GLP-3" is a nickname, not the name of a target in retatrutide's mechanism. Retatrutide is a triple agonist: it turns on GIP, GLP-1, and glucagon signals. The three-target description does not mean it has FDA approval.

Are either of them available as pills?

No. Both were tested as weekly shots, and neither has an approved form. If you'd prefer a pill, a doctor can talk with you about approved oral options such as Foundayo, which is a different drug. (Trial form; FDA oral approval).

Can a compounding pharmacy make survodutide or retatrutide?

The FDA says retatrutide cannot be used in compounding under federal law. Neither drug is part of any FDA-approved medicine, and the FDA warns about both being sold as "research" products. Compounded drugs are not FDA-approved. The FDA warning does not make a product marketed as survodutide an authorized compounding option; we did not verify any lawful commercial compounding offer for it.

Should I stop Zepbound to wait for retatrutide?

No. Don't stop a medicine you're on because of a trial headline. Talk with the doctor who manages your prescription about whether anything should change.

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

All checked October 15, 2026 unless noted.

1. Eli Lilly. TRIUMPH-1 topline results. May 21, 2026. Sponsor-reported efficacy, safety, and selected extension details.
2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. NEJM, published September 29, 2026. Original abstract read; full article not retrieved.
3. Eli Lilly. TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027. July 23, 2026.
4. Eli Lilly. TRIUMPH-2 detailed results. September 29, 2026. Sponsor-reported efficacy and detailed safety data.
5. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). The Lancet, published online September 29, 2026. Original abstract read.
6. le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. NEJM, June 7, 2026. Full paper and Table 3 checked using the publisher-hosted PDF.
7. Boehringer Ingelheim. SYNCHRONIZE-1 and SYNCHRONIZE-MASLD results. June 7, 2026; current release carries a correction from 10.8% to 11.3% for the lean-loss ratio.
8. Wharton S, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. NEJM, October 1, 2026. Full paper, Table 3, and supplement checked in a copy of the published article and supplement.
9. Boehringer Ingelheim. SYNCHRONIZE-2 results and additional muscle analysis. October 1, 2026.
10. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. NEJM, 2024. Full publisher-hosted paper checked, including the planned-treatment results.
11. Kaplan LM, et al. Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD. Nature Medicine, June 7, 2026; current corrected article checked. The article links its August 25, 2026 correction.
12. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized Phase 2a trial. Nature Medicine, June 10, 2024. Full article checked.
13. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 2023. Weight-loss result and heart-rate pattern.
14. Boehringer Ingelheim. Survodutide Phase 2 weight-loss results. June 23, 2023. Actual- versus planned-treatment analysis of the 46-week trial; peer-reviewed trial abstract.
15. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated October 1, 2026.
16. Lilly Medical. Is there an expanded access program for retatrutide?. Last reviewed by Lilly August 26, 2026; retrieved October 15, 2026.
17. U.S. Food and Drug Administration. Foundayo approval announcement. April 1, 2026.
18. U.S. Food and Drug Administration. Wegovy prescribing information. June 2026 label; injection-specific MASH indication and accelerated-approval conditions. FDA MASH approval announcement, August 2025.
19. U.S. Food and Drug Administration. First approval for noncirrhotic MASH with liver scarring: Rezdiffra. March 14, 2024.
20. Eli Lilly. Zepbound prescribing information. Revised August 2026; Study 1, 72-week weight-loss results.
21. U.S. Food and Drug Administration. PDUFA VII performance goals, fiscal years 2023–2027. Original new-drug and biologics application action goals.
22. Lilly Trials. TRIUMPH-5 official listing, linked to NCT06662383. Trial end listed as December 2026; no results publication date established.
23. ClinicalTrials.gov. SYNCHRONIZE-CVOT, NCT06077864; LIVERAGE, NCT06632444; retatrutide expanded access, NCT07629401. Study identifiers, not promises of current local enrollment.
24. Ro. Weight loss program. Medication offerings and insurance versus cash-pay distinctions checked October 15, 2026; no checkout or personal coverage test.
25. National Capital Poison Center. Poison Control. Telephone and emergency-help guidance.
26. The RX Index. Find My GLP-1 Path, live site tool description, editorial team, and methodology. Description and link checks, not a clinical or insurance assessment.